Literature DB >> 24553324

Progression to the persistent form in asymptomatic paroxysmal atrial fibrillation.

Keitaro Senoo1, Shinya Suzuki, Takayuki Otsuka, Koichi Sagara, Shunsuke Matsuno, Hiroto Kano, Tokuhisa Uejima, Yuji Oikawa, Junji Yajima, Kazuyuki Nagashima, Hajime Kirigaya, Hitoshi Sawada, Tadanori Aizawa, Takeshi Yamashita.   

Abstract

BACKGROUND: This study investigated the progression of paroxysmal atrial fibrillation (AF) to the persistent form in Japanese asymptomatic AF patients. METHODS AND
RESULTS: Data were derived from a single hospital-based cohort in the Shinken Database 2004-2012 (n=19,994), in which 1,176 patients were diagnosed as having paroxysmal AF. AF progression occurred in 115 patients (6.0%/year) during the mean follow-up period (1,213±905 days). Although patients who were asymptomatic at the initial visit (n=468) had a low-risk profile compared with symptomatic patients, they had greater AF progression at follow-up (unadjusted hazard ratio, 1.611; 95% CI: 1.087-2.389; P=0.018). Absence of symptoms, male sex, and cardiomyopathy were independent predictors for AF progression in the multivariate model. It was noted that asymptomatic patients were less likely to undergo pulmonary vein isolation (PVI). In addition, the interaction term between asymptomatic AF and absence of PVI could be another independent predictor for AF progression. Prognosis was similar between asymptomatic and symptomatic patients with AF.
CONCLUSIONS: Irrespective of low-risk profile, patients with asymptomatic paroxysmal AF had greater progression of AF compared with symptomatic patients. This paradoxical result appeared to be the result of less intensive clinical management, including invasive rhythm control.

Entities:  

Mesh:

Year:  2014        PMID: 24553324     DOI: 10.1253/circj.cj-13-1272

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  8 in total

Review 1.  Global epidemiology of atrial fibrillation.

Authors:  Faisal Rahman; Gene F Kwan; Emelia J Benjamin
Journal:  Nat Rev Cardiol       Date:  2014-08-12       Impact factor: 32.419

Review 2.  Indications For AF Ablation: Before Or After The Failure Of Antiarrhythmic Drug Therapy?

Authors:  Akira Kimata; Yoko Ito; Kentaro Yoshida
Journal:  J Atr Fibrillation       Date:  2014-10-31

3.  Long-term Prognosis of Paroxysmal Atrial Fibrillation and Predictors for Progression to Persistnt or Chronic Atrial Fibrillation in the Korean Population.

Authors:  Sung Il Im; Kwang Jin Chun; Seung-Jung Park; Kyoung-Min Park; June Soo Kim; Young Keun On
Journal:  J Korean Med Sci       Date:  2015-06-10       Impact factor: 2.153

4.  Quasi-Randomized Trial of Effects of Perioperative Oral Hygiene Instruction on Inpatients with Heart Diseases Using a Behavioral Six-Step Method.

Authors:  Chie Omori; Daisuke Ekuni; Yumiko Ohbayashi; Minoru Miyake; Manabu Morita
Journal:  Int J Environ Res Public Health       Date:  2019-11-01       Impact factor: 3.390

5.  Two Cases of Multiple Thromboembolism With Asymptomatic Atrial Fibrillation.

Authors:  Yudai Tanaka; Michiaki Matsumoto; Takaharu Yahata; Takashi Mineki; Koji Oiwa
Journal:  Cureus       Date:  2022-01-26

6.  Impact of periodontitis as representative of chronic inflammation on long-term clinical outcomes in patients with atrial fibrillation.

Authors:  Sung Il Im; Jinho Heo; Bong Joon Kim; Kyoung-Im Cho; Hyun Su Kim; Jung Ho Heo; Jin Yong Hwang
Journal:  Open Heart       Date:  2018-04-25

7.  Screening for atrial fibrillation and other arrhythmias in primary care.

Authors:  Kam Cheong Wong; Cindy Kok; Simone Marschner; Tim Usherwood; Clara K Chow
Journal:  BMC Fam Pract       Date:  2020-05-06       Impact factor: 2.497

8.  Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis.

Authors:  Fadi Alijla; Chepkoech Buttia; Tobias Reichlin; Salman Razvi; Beatrice Minder; Matthias Wilhelm; Taulant Muka; Oscar H Franco; Arjola Bano
Journal:  Cardiovasc Diabetol       Date:  2021-12-07       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.